← Back to News
Addiction TreatmentNovember 14, 2026

Addiction Treatment Myths: 8 Beliefs to Unlearn

Addiction treatment is full of confident advice, and much of it is wrong. Some of it comes from old rehab culture, some from clinic marketing, and some from the understandable hope that one intervention will settle everything. This guide takes eight common beliefs about addiction treatment, including beliefs about detox, medication and ibogaine, and sets each one against what is actually known. Where the honest answer is that no one knows, it says so.

Which addiction treatment myths get people hurt?

The myths below are not harmless. Several lead directly to decisions that end in an emergency room, or worse. A few are simply expensive. All of them are easier to drop once you can see where they came from, so each one is paired with the belief behind it and what replaces it.

Myth 1: Detox is the same as addiction treatment

Detox manages the physical process of stopping a substance. It is a medical event that lasts days, and when it is over, the brain that learned the habit is still there, along with the people, places and stresses that fed it. Treatment is the longer work that follows: therapy, medication where appropriate, changes to daily life, and a concrete plan for the first bad week.

Levels of care exist for this reason. Residential programs, intensive outpatient programs and ordinary weekly therapy are different intensities of the same work, and most people move between them over time instead of finishing one and being done.

The same distinction applies to ibogaine. At its best, ibogaine interrupts physical dependence and opens a window of reduced craving. It does not do the months of work that follow, and a program that sells it as the whole answer is overselling it. A clear overview of what ibogaine addiction treatment can and cannot do belongs at the start of any decision, not the end.

Myth 2: You have to hit rock bottom first

Waiting for a bottom made sense to people who believed motivation only arrives through catastrophe. With fentanyl spread through the illicit opioid supply, the bottom is often death. Treatment works for people who are ambivalent, people who were pushed into it by family, and people who still have a job and a house. Readiness helps. It is not a requirement for starting, and most people become more willing once they are inside a program and feeling better.

The practical version of this myth is "I will go when things get bad enough." With a supply that can kill on the first unlucky dose, the threshold for bad enough is not something you get to set. If you are reading this, the question is already live.

Myth 3: Methadone and buprenorphine just swap one addiction for another

Methadone and buprenorphine are prescribed medications with decades of evidence behind them, and people on a stable dose can work, drive and raise children. Physical dependence on a prescribed medicine is not the same thing as the chaos of an illicit habit. Some people stay on them for years and do well. Others want off, or have not done well, and go looking for alternatives such as ibogaine. Both paths are legitimate, and the right one depends on the person, not on a slogan.

What the myth gets wrong is the goal. The goal of addiction treatment is a life that works, not a body free of every molecule. A person on a stable dose who has stopped using illicit drugs has achieved most of what treatment is for, whether or not they later choose to come off.

What do people get wrong about ibogaine and the body?

Myth 4: Because ibogaine comes from a plant, it is gentle on the body

People have died during and after ibogaine treatment, in clinics as well as outside them. Heart rhythm problems are the suspected cause in many of those deaths. Ibogaine prolongs the QT interval, the part of the heartbeat during which the heart recharges, and monitored hospital patients have reached dangerous QT intervals, and so have people dosed at home or in underground settings. Monitoring can catch a dangerous rhythm early enough to treat it; it does not prevent one, and it can miss one.

No one knows how often people die from ibogaine, because there is no registry and much of the treatment happens where nothing is reported. That is the honest baseline, and any program that tells you otherwise is guessing in its own favour. It is also why the people who decide to go anyway should go with their eyes open, with their own physician aware of the plan, and with a clinic that screens hard enough to turn some people away.

A few practical points follow. Ask whether potassium and magnesium are checked and corrected before dosing, and again after vomiting, which is common. Magnesium is a reasonable precaution, not a proven protection, and no study has shown it prevents arrhythmia. Ibogaine is cleared by a liver enzyme whose activity varies from person to person, which is why some medicines raise ibogaine levels. Certain antidepressants block that enzyme and need weeks to wash out, not days. Stopping one has its own risks and is done only with the prescriber who prescribed it, never on a clinic's timetable alone.

Myth 5: After ibogaine, opioids are no longer dangerous

The opposite is closer to the truth. Opioid tolerance falls after treatment, by an amount no one can predict, so a dose used before can be a fatal overdose. Opioids may also act more strongly than expected in the weeks afterward. Anyone leaving an ibogaine program should leave with naloxone, the people around them should know how to use it, and anyone who sees an overdose should call emergency services.

Fentanyl adds a layer of uncertainty that is easy to miss. No published ibogaine study has enrolled a fentanyl-using population, so what is known about ibogaine and heroin or methadone does not transfer cleanly. A negative fentanyl test strip does not make a drug safe either; strips miss some analogues and cannot tell you how much is in a dose. The questions to ask before choosing ibogaine for fentanyl addiction are different from the ones that applied a decade ago.

What do people get wrong about medication, clinics and the trip home?

Myth 6: Methadone and Suboxone are your problem to sort out before you arrive

Stopping methadone or buprenorphine carries its own overdose risk, and it is done with a prescriber, not alone. Any switch before dosing is done by the treating clinic's physicians, where the treatment takes place, and not arranged at home. Methadone takes days to clear and itself prolongs the QT interval. Buprenorphine is long-acting and binds tightly; how long it takes to clear depends on its form and dose, and a long-acting monthly injection can stay detectable for a year or more. Routine urine screens can miss it, so ask how the clinic confirms it has cleared.

Ask how many days before dosing each medication must stop and what you would take in the meantime. In the United States no prescriber can lawfully write a prescription for morphine, methadone or another Schedule II opioid to treat opioid use disorder, and methadone for addiction comes only from a certified opioid treatment program. So your own doctor or program will not do the transition for you, and no article can. Never bridge with opioids from any other source: those bought outside a pharmacy may contain fentanyl, and tolerance is already falling. Before leaving, settle with the treating physician whether and when methadone or buprenorphine restarts, and who would do it.

Myth 7: A clinic license in Mexico means the government has signed off on ibogaine

Mexico has not scheduled ibogaine, which makes it unregulated, not approved. A clinic can hold a health establishment license, and that license says nothing about ibogaine; it is not an approval of the treatment. "Licensed" and "approved" are not the same word. Ibogaine is a Schedule I controlled substance in the United States, which is why the treatment happens abroad in the first place.

The same scepticism applies to safety claims. A clinic's statement that it has never had a death cannot be checked, because no outside body audits it. Treat it as a claim, not a record. Ask instead whether physicians are on site through the night, what the emergency plan is, how far the nearest hospital is, and what happens to a patient whose ECG changes at two in the morning.

Myth 8: You can fly home the day after treatment

The QT interval commonly stays long past the first day, and in reported cases for more than a week. Travel after treatment follows a normal ECG, not a set number of days. You will need help walking for at least a day, and the risk of a dangerous rhythm lasts at least the first week and until an ECG is normal. Fainting, a racing or irregular heartbeat or a seizure is an emergency at any time in that window.

Many people also feel physically wrung out for several days: unsteady, foggy, sensitive to light and noise. That is normal, and it is one more reason the first week is not the time to be alone in an airport.

Until the ECG is normal, no new medicine is started, anti-nausea drugs included, without asking a prescriber who knows about the ibogaine whether it affects the QT interval. Build that into the travel plan before you book a return flight, and expect the cost of a few extra nights to be part of the real price.

What should you ask instead?

Myths survive because they are simpler than the real questions. The real questions are short, and a serious program will answer them without flinching. Who screens me, and what will they refuse to treat? What happens if my heart rhythm changes during dosing? How do you confirm my methadone or buprenorphine has cleared? What will I leave with, and who follows up in the first month?

Write the answers down and compare them across programs. Vague answers, or answers that lean on reassurance instead of specifics, are themselves information.

Addiction treatment, with or without ibogaine, goes better when the person choosing it understands what each option can and cannot do. The ibogaine treatment guide covers screening, medication interactions, costs and aftercare in more detail, so you can walk into any conversation with a clinic already knowing what to ask.